Clinical trial · Observational
cDC1 Prognostic and Predictive Role in Non-Small-Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): access to human body samples by another existing cohort
Summary
Brief summary (as posted)
The response rate of immune checkpoint inhibitors remains relatively low and the identification of the new predictive biomarkers is necessary. The rare population of cDC1 is very interesting, as its mouse counterparts is essential for the cross presentation of tumor-associated antigens, tumor immunity and response to immunotherapies. Their role in humans has not been studied. This proposal aims to study the prognostic role of cDC1 in a cohort of patients with advanced NSCLC, possibly demonstrating their positive predictive value of immune checkpoint inhibitors response.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| This is a non-interventional study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- cDC-1 positive
- description
- cDC-1 positive patients according to RNAseq and in situ analysis
- interventionNames
- Other: This is a non-interventional study
- label
- cDC-1 negative
- description
- cDC-1 negative patients according to RNAseq and in situ analysis
- interventionNames
- Other: This is a non-interventional study
Primary outcomes (1)
- measure
- Progression free survival (PFS)
- timeFrame
- 1 year
- description
- To validate the cDC1 infiltration as predictive biomarker of pembrolizumab response
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * NSCLC diagnosis * Advanced disease (Stage III-IV) according to the TNM 7th/8th classification * Patients have to have performed pembrolizumab in first line if PD-L1 ≥ 50% or cisplastin-based chemotherapy if PD-L1 \< 50% * FFPE material available from diagnostic sample Exclusion Criteria: \-
References
Publications (0)
Data not yet available